ArticleAnnals of clinical and translational neurology2025
A Novel C19orf47-AKT2 Chimeric RNA Generated by Cis-Splicing of Adjacent Genes Is Associated With Glioblastoma Prognosis.
Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveMalignant gliomas pose significant therapeutic challenges. This study aimed to identify and characterize a novel chimeric RNA in glioma and assess its clinical and functional significance for precision treatment.
methodsThe C19orf47-AKT2 chimeric RNAs were identified through RNA sequencing and validated by polymerase chain reaction. Their expression in tumor core and peritumoral tissues was quantified and compared via quantitative polymerase chain reaction, whereas their prognostic significance in glioblastoma was assessed using Kaplan-Meier analysis. The formation mechanism was investigated through genomic analysis, and western blotting was performed to assess fusion protein translation. The CCK-8 assay was performed to assess the chimeras' effect on glioma proliferation.
resultsC19orf47-AKT2 chimeric RNAs were detected in 88.9% (144/162) of glioma core tissues, significantly higher than in peritumoral tissues (65.2%, 30/46, p < 0.001). Quantitative analysis showed no significant expression difference between variants in peritumoral tissues, but the C19orf47e9-AKT2e2 variant was significantly more abundant in tumor core tissues. High expression of this variant correlated with poor prognosis in glioblastoma patients. Mechanistically, C19orf47-AKT2 chimeras were generated via cis-splicing of adjacent genes, without DNA rearrangement. Although Western blot confirmed the translation of C19orf47e9-AKT2e3 into a fusion protein in 293 T cells, no endogenous fusion protein was detected in glioblastoma tissues or cells. Functional assays demonstrated that downregulation of C19orf47-AKT2 chimeras significantly suppressed the proliferation of patient-derived glioblastoma cells.
interpretationThis study identifies novel C19orf47-AKT2 chimeras formed through cis-splicing, which might function as noncoding RNAs to promote glioblastoma proliferation. These chimeras may serve as potential prognostic markers and therapeutic targets in gliomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.